Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
03:01pm, Friday, 29'th Nov 2024
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
12:35pm, Wednesday, 27'th Nov 2024
Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
11:00am, Wednesday, 27'th Nov 2024
The mean of analysts' price targets for Sarepta Therapeutics (SRPT) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step
03:02pm, Friday, 08'th Nov 2024
Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
10:20am, Thursday, 07'th Nov 2024
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
02:10am, Thursday, 07'th Nov 2024
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communic
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
07:36pm, Wednesday, 06'th Nov 2024
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
08:30am, Wednesday, 23'rd Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasd
2 High-Flying Growth Stocks With Massive Upside Potential
09:53am, Thursday, 17'th Oct 2024
These innovative drugmakers have potential catalysts ahead.
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
08:15am, Thursday, 03'rd Oct 2024
These two could become direct competitors relatively soon.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:39pm, Monday, 30'th Sep 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2024 (the “Grant Date�
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
08:30am, Thursday, 26'th Sep 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 29th Annual Congress of the World Muscle So
Sarepta Therapeutics Muscles Up In DMD Race
11:59pm, Wednesday, 18'th Sep 2024
Sarepta's Elevidys received expanded FDA approval to treat both ambulatory and non-ambulatory DMD patients aged four and above. Although Elevidys missed its primary endpoint, it demonstrated success o
3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
11:40am, Wednesday, 18'th Sep 2024
Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.
